Consilium Strategic Communications is a global leader in providing trusted, healthcare-focused strategic IR and financial PR counsel to corporations, Boards, senior decision makers and executives.

From offices in Europe and USA, Consilium Strategic Communications’ senior team provides cross-border comprehensive financial and corporate healthcare communications advice to some of the world’s most prominent corporations around-the-clock.

Client News


Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress

Lyxumia® royalties and milestone revenue of DKK 20.6 million / EUR 2.7 million Net operating expenses of DKK 176.2 million / EUR 23.6 million for the period   Net result of DKK -183.7 million / EUR -24.6 million Financial guidance for 2015 unchanged     Significant pipeline progress in Q3 2015: Lixisenatide (Type 2 diabetes) application for regulatory approval in the US accepted for review by the FDA LixiLan (Type 2 diabetes) showed positive results in two Phase III trials and Sanofi expects regulatory submission in the US in Q4 2015 and in the EU in Q1 2016  Novel long-acting GLP-2 analogue, ZP1848, advanced into Phase II development for the treatment of Short Bowel Syndrome Stable glucagon analogue, ZP4207, showed positive results in a multiple-dose Phase Ib trial for better control of hypoglycemia  Copenhagen, 5 November 2015 – Zealand Pharma A/S (“Zealand”) (CVR no. 20 04 50 78) announces financial results on target for the first nine months of 2015, from 1 January to September 30, and reports that  significant product and pipeline milestones have been met and announced in Q3 2015.    Click to read more...


Zealand is ready to take next steps in a diligent growth strategy for accelerated value creation: From peptide to patient

Zealand management yesterday presented the strategic direction for Zealand at a Capital Markets Day in New York Building on a strong trajectory, the company will focus to progress select proprietary specialist medicines through to registration, retaining full ownership and value control Pipeline expansion will continuously leverage Zealand’s leading-edge peptide expertise, combined with external innovation of new medicines Strong news flow from partnered and proprietary programs expected to continue through 2016   Click to read more...


Oxford BioMedica - Business Update

Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce the following business update. The Group continues to make good progress in line with its strategy across the business model, leveraging its extensive patent estate and know-how (intellectual property or “IP”) and its expertise and capabilities in the field of lentiviral vectors.  Recent developments across the three key components of the Group’s business model are summarised below.  The Group has recently introduced a numbering system for product development candidates (Central nervous system products will be numbered OXB-1XX, ophthalmology products OXB-2XX, and oncology candidates OXB-3XX). Click to read more...


Advanced Medical Solutions Group plc - 510(k) Premarket notifications to market sutures in the US

Winsford, UK, 4 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that it has received notice of further  Premarket 510(k) approvals, successfully adding to its first US suture approval from early 2015, thereby covering the vast majority of the rest of the suture product portfolio. With only one more suture type still awaiting US market approval, the Group is now well positioned to launch a comprehensive range of sutures into the US in mid 2016 through a combination of its branded and unbranded routes to market.  Click to read more...


Advanced Medical Solutions Group plc - FDA Approves Extended Product Claims for LiquiBand® Exceed™ Topical Skin Adhesive

Winsford, UK, 3 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.   Click to read more...


Quanta appoints Dr Francesco Granata as Non-Executive Director

Alcester, Warwickshire, UK, 3 November 2015: Quanta Fluid Solutions Ltd (“Quanta” or the “Company”), a pioneer of advanced haemodialysis solutions, today announces the appointment of Dr Francesco Granata to the Company’s Board as an independent Non-Executive Director, with immediate effect. Click to read more...


Biocartis to participate in key investor conferences in November 2015

Mechelen, Belgium, 3 November 2015: Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced that its Chief Executive Officer Rudi Pauwels, Deputy CEO & Managing Director Hilde Windels and Chief Financial Officer Ewoud Welten, will be participating in key investor conferences in November 2015: Click to read more...


Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting

Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for presentation at the 57th Annual Meeting in Orlando, Florida on December 7, 2015.  Click to read more...


MDxHealth Provides Third Quarter 2015 Business Update

Revenue for the first nine months up 44% to $11.9 million 67% increase in case volume from previous quarter and 30% year-on-year growth Expansion of uro-oncology product offering and global commercial strategy IRVINE, CA, and HERSTAL, BELGIUM – November 3, 2015 – MDxHealth SA (Euronext: MDXH.BR) today announced its third quarter 2015 Business Update for the period ended September 30, 2015. Click to read more...


Mainstay Medical Applies for CE Mark for ReActiv8®

Dublin – Ireland, 2 November 2015 – Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces it has submitted an application for CE Mark for ReActiv8. The submission represents a further key step towards commercialisation of ReActiv8 in Europe. Click to read more...


Inivata Announces Appointment of Jeffrey Buchalter as Chairman

Cambridge, UK, 29 October 2015. Inivata Limited, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, announces the appointment of Jeffrey Buchalter as a Non-Executive Director and Chairman of the Board.  Click to read more...


Zealand reports Lyxumia® royalty revenue for Q3 2015 and that Sanofi confirms expected next steps in the US regulatory process

Royalty revenue to Zealand from Sanofi’s sales of Lyxumia® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9 million in Q3 2015, a 20% increase over Q3 2014 A US regulatory decision on lixisenatide by the FDA is expected in Q3 2016 Sanofi expects regulatory submission of LixiLan in Q4 2015 in the US and in Q1 2016 in Europe Copenhagen, 29 October 2015 – Zealand announces that royalty revenue on Sanofi’s global sales of Lyxumia® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9